Mirum Pharmaceuticals (NASDAQ: MIRM) reported a strong Q1 2026, showcasing a 43% year-over-year revenue growth, primarily driven by its lead drug, Livmarli, which generated $159.9 million in net sales. The company raised its full-year revenue guidance to between $660 million and $680 million, indicating a 26% increase at the midpoint. However, despite these positive metrics, MIRM shares have declined approximately 12% post-earnings, largely due to heightened operating expenses linked to a recent acquisition.

The market’s reaction highlights the inherent risks associated with mid-cap biotech firms, particularly those that are not yet profitable. Mirum’s substantial operating costs, including $949 million in Q1, have raised concerns among investors, especially as the company navigates its path to profitability. The proposed $600 million offering of convertible senior notes adds another layer of complexity, though it could potentially fund future growth initiatives.

For investors, this dip may present a buying opportunity, especially given the stock’s historical performance and analyst price target of $137.08, suggesting over 40% upside. However, the 17% short interest indicates potential selling pressure, necessitating careful consideration of Mirum’s growth trajectory and market positioning.

Source: marketbeat.com